JAK inhibitor labeling in Canada updated to include risks of MACE, fatal VTE and cancer for tofacitinib (Xeljanz) (also applied to Cibinqo, Inrebic, Jakavi, Olumiant, Rinvoq Xeljanz) https://t.co/FEbHE4wN3I https://t.co/EN80i9cY5h

Dr. Chao will be covering PsA and AS for the RheumNow team at #ACR22. “I’m looking forward to the exciting hybrid format of both in person and virtual meeting this year!” Follow @doctorRBC for real-time #ACR22 coverage. https://t.co/3sbBhVPPZ2

Introducing Dr. Akhil Sood, who will be covering #ACR22 on behalf of RheumNow. He is excited to learn more about the cutting-edge research in the field of Rheumatology & Immunology. Follow him @AkhilSoodMD for real-time coverage! https://t.co/hXw2CMrwKF

🆕Recommendation provided by Pharmacovigilance Risk Assessment Committee (#PRAC) about Janus kinase inhibitors #JAKi ⏩EMA recommends measures to minimise risk of serious side effects with #JAKi for chronic inflammatory disorders. https://t.co/YqaX7UxtUA https://t.co/dCJbqanAxF

Think about checking Ig levels prior to Rituximab administration. Low IgM was most common after RTX in RA. The following are risk factors for hypogammaglobulinemia: 🧪 Older age 🧪 Use of steroids 🧪 Repeated doses of RTX 🧪 Low Ig at baseline https://t.co/oOjqnmFdYt

RheumNow #ACR22 reporter, Dr. Bella Mehta, will be covering SLE, gout and auto inflammatory topics this year. “I am looking forward to meeting collegues at ACR after 2 years!” -Dr. Mehta Follow @bella_mehta for real-time coverage during #ACR22. https://t.co/QQM2NrObPR

Follow our newest #ACR22 reporter, Dr. Julian Segan ( @JulianSegan)! “I am looking forward to is meeting all my rheumatology Twitter heroes!” Follow @RheumNow and our reporters for real-time #ACR22 coverage. https://t.co/7axxfOV6W8

China study of 109 w/ MPO+ vasculitis (MPO-AAV), 23 w/ anti-GBM & 20 Double positive (MPO+ GBM+) (DPP) pts showed DPP pts were older(p=0.007), higher creatinine & lower GFR, & had multi-organ damage (cardiac) outside the kidney https://t.co/3aGPnfVDrs https://t.co/E557RLogCE

Drug-induced Hepatotoxicity - many Rheum drugs on the list: Tylenol, azathioprine, allopurinol, cyclosporine, dapsone, gold, MTX, 6-MP, NSAIDs, ASA, SSZ, Minocin... https://t.co/wuoVrDgesq https://t.co/SAWPdsQ6I3

What is RheumNow ACR reporter, Dr. Rachel Tate, most looking forward to at #ACR22? “Onsite, in person learning!” Follow @uptoTate for real-time #ACR22 coverage! https://t.co/nMw015dpdl

Opportunistic infections in #PsA pts on b/tsDMARDS is low. Metanalysis 47 studies, 17,197 pts - OI risk by MOA:1) JAK inhib 2.72%, 2) anti-IL-17 1.18%, 3) anti-IL-23 0.24% , 4) TNFi 0.01%. H. zoster w/ JAKi= 2.53% & Candida risk w/ IL-17=0.97% https://t.co/a5fJcWTxnL https://t.co/GQKoV7Hg6m

GSK announced they will halt development of Otilimab (anti-GM-CSF mAb) to treat #RA; decisioin based on negative results from phase 3 ContRAst-3 study, that failed to meet ACR20 primary endpoint in RA pts who failed bDMARDs or JAKi https://t.co/cDqcYKOjSa https://t.co/7rB4TYsWnZ